Clariant (CLN) Q3 2025 earnings summary

Executive summary

• Q3 2025 sales reached CHF 906 million, down 3% in local currency and 9% in CHF, with EBITDA before exceptional items up to CHF 162 million (17.9% margin), driven by performance improvement and cost management.

• 9M 2025 sales were CHF 2.887 billion, down 1% in local currency, with EBITDA margin before exceptional items up 160 bps to 18.0%.

• Performance improvement and savings programs delivered CHF 31 million in savings YTD, with CHF 80 million targeted by 2027 and CHF 63 million restructuring charges recognized YTD.

• Board of Directors to be reduced from 11 to 8 members, enhancing governance, independence, and diversity.

Financial highlights

• Q3 EBITDA before exceptional items increased by 5% to CHF 162 million (margin 17.9%, up 230 bps YoY); reported EBITDA up 14% to CHF 159 million.

• 9M 2025 EBITDA before exceptional items was CHF 521 million (18.0% margin, up 160 bps YoY); reported EBITDA for 9M was CHF 450 million, impacted by CHF 63 million restructuring charges.

• Q3 sales bridge: Price +1%, Volume -4%, Currency -6%.

• CapEx guidance lowered to CHF 180 million, reflecting a shift to maintenance-oriented spending after major investments.

Outlook and guidance

• 2025 local currency sales growth expected at the lower end of the 1–3% range due to weak industrial production and consumer sentiment.

• EBITDA margin before exceptional items confirmed at 17–18% for 2025; medium-term targets of 19–21% margin and 4–6% CAGR sales growth by 2027.

• CapEx targeted at CHF 180 million; restructuring charges of CHF 75 million expected for 2025.

• Continued focus on cash conversion towards a 40% target.